| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continue...
																	HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $8 to...
																	
																	Guidance for full-year 2025Group revenues expected in a range of € 760 - 800 m (2024: € 797.0 m)R&D expenditures are expect...
																	
																	
																	Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to SandozUn...